LGC eBook - 2017 - 17

Point-of-Care Molecular
Diagnostics Evolve
Moving Toward True Portability?
Patricia Dimond, Ph.D.

Kalorama Information noted that the emerging
area of rapid POC molecular testing attracted
over $650 million in investments and financings
17

| GENengnews.com

between 2009 and 2013, while a 2014 Frost &
Sullivan report predicted that molecular testing,
particularly the overall growth of the global
infectious diseases diagnostics market, will
approach $12.78 billion by 2018.
The introduction of CLIA waived tests (i.e., assays
approved for use by healthcare providers in nontraditional laboratory sites like physician offices,
emergency rooms, health department clinics,
pharmacy clinics, and other healthcare facilities)
is considered a key POC market driver.
Funding that drives the development of POC
technologies comes from multiple sources,

ADDITIONAL CONTENT
GMP custom oligos
and commercial
services are at the
heart of our core
business to ensure
your success.
Learn More

sturti /iStock

A

s described by the NIH, point-of-care (POC)
instruments combine multiple analytical
functions into self-contained, portable devices
that can be used by nonspecialists to detect
and diagnose disease. They can also enable the
selection of optimal therapies through patient
screening and monitoring of a patient's response
to a chosen treatment. These devices have
attracted public and private funding, as well
as considerable investment from large
diagnostic companies.

https://www.biosearchtech.com/services/gmp-commercial-services?utm_source=gen&utm_medium=ebook&utm_content=text&utm_campaign=LGC_PCR http://www.GENengnews.com

LGC eBook - 2017

Table of Contents for the Digital Edition of LGC eBook - 2017